GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
JCI accreditation is recognized globally
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Exploring new opportunities within the fast-growing market of microfluidics
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Subscribe To Our Newsletter & Stay Updated
